Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024. Statistically speaking, that's a real negative for future earnings. To wit, the company did not generate one whit of ...

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

Sarepta Therapeutics SRPT posted third-quarter 2024 adjusted earnings per share (EPS) of 62 cents, which beat the Zacks ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Sarepta Therapeutics (NASDAQ: SRPT) Q3 2024 Earnings Call Nov 06, 2024, 4:30 p.m. ET ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...